Effects of alprostadil on blood rheology and nucleoside metabolism in patients affected with lower limb chronic ischaemia

Clinical Hemorheology and Microcirculation

Volumn 24, Issue 1, 2001, Pages 49-57

  Acciavatti, A ^a   Pasini, F Laghi ^a,b   Capecchi, P L ^a,b   Messa, G L ^a   Lazzerini, P E ^a,b   De Giorgi, L ^a   Acampa, M ^a   Di Perri, T ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Adenosine; Alprostadil; Haemorheology; Ischaemia; Oxygen transport

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ADENOSINE; FIBRINOGEN; HEMOGLOBIN; NUCLEOSIDE; OXYGEN; PROSTAGLANDIN E1; PROTEIN P50;

ADULT; ARTICLE; BLOOD; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; MALE; METABOLISM; OXYGEN TRANSPORT; WALKING;

ALPROSTADIL; BLOOD COAGULATION; EXTREMITIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; NUCLEOSIDES; PERIPHERAL VASCULAR DISEASES; RHEOLOGY;

EID: 0035073570     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. H. Bardenheuer and J. Schrader, Relationship between myocardial oxygen consumption, coronary flow, and adenosine release in an improved isolated working heart preparation of guinea pig, Circ. Res. 51 (1983), 263-271.
2. H. Bardenheuer and J. Schrader, Supply-to-demand ratio for oxygen determines formation of adenosine by the heart, Am. J. Physiol. 250 (1986), H113-H118.
3. J.J. Belch, A. McKay, B. McArdle, P. Leiberman, J.G. Pollock, G.D. Lowe, C.D. Forbes and C.R. Prentice, Epoprostenol (prostacyclin) and severe arterial disease, A double blind trial, Lancet 1 (1983), 315-317.
4. J.J.F. Belch, A. Sinibaldi and C.D. Forbes, The effects of ZK-36374 (Iloprost) on white cell behaviour, in: Prostacyclin and Its Stable Analogue Iloprost, K. Schrör and R.J. Grylewski, eds, Springer-Verlag, Berlin, 1986, pp. 92-102.
5. J.J. Belch, P.R. Bell, D. Creissen, J.A. Dormandy, R.C. Kestler, R.F. McCollum, Y. Mizushima, C.V. Ruckley, J.H. Scurr and J.H. Wolfe, Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin El prodrug, in patients with intermittent claudication, Circulation 95 (1997), 2296-2302.
6. R.M. Berne, Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow, Am. J. Physiol. 204 (1963), 317-322.
7. R. Bünger, F.J. Haddy and E. Gerlach, Coronary response to dilating substances and competitive inhibition by theophylline in the isolated perfused guinea pig heart, Pflüngers. Arch. 358 (1975), 213-224.
8. P.L. Capecchi, F. Laghi Pasini, G. Cati, M. Colafati, A. Acciavatti, L. Ceccatelli, S. Petri, A. de Lalla and T. Di Perri, Experimental model of short-time exercise-induced preconditioning in POAD patients, Angiology 48 (1997), 469-480.
9. L.A. Carlson, E. Irion and L. Oroe, Effect of infusion of prostaglandin E1 on blood platelets in man, Life Sci. 7 (1968), 85-90.
10. P.C. Clifford, M.F.R. Martin, E.J. Sheddon, J.D. Kirby, R.N. Baird and P.A. Dieppe, Treatment of vasospastic disease with prostaglandin E1, Br. Med. J. 281 (1980), 1031-1034.
11. A.R. Collinson, J. Peuhkurinen and J.M. Lowenstein, Regulation and function of 5′-nucleotidases, in: Topics and Perspectives in Adenosine Research, G. Gerlach and B.F. Becker, eds, Springer-Verlag, Berlin, 1987, pp. 133-144.
12. A. Denssen, G. Moser and J. Schrader, Contribution of coronary endothelial cells to cardiac adenosine production, Pflüngers. Arch. 406 (1986), 608-614.
13. C. Diehm, A. Kuhn, R. Strauss, C. Hubsch-Muller and W. Kübler, Effects of prostaglandin El and naftidrofyryl infusion therapy in patients with intermittent claudication, a controlled study, Vasa 28(Suppl.) (1989), 24-26.
14. A. Edlund, A. Siden and A. Sollevi, Evidence for an antiaggregatory effect at physiological concentrations and for its role in the action of dipyridamole, Thromb. Res. 45 (1989), 183-190.
15. P.R. Emmons, P.R. Hampton, M.J.C. Harrison, A.J. Honour and J.R.A. Mitchell, Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo, Br. Med. J. 2 (1967), 468-472.
16. Y.Y. Fan, K.S. Ramos and R.S. Chapkin, Cell cycle related inhibition of mouse vascular smooth muscle cell proliferation by prostaglandin E1: relationship between prostaglandin E1 and intracellular cAMP levels, Prostaglandin. Leukot. Essent. Fatty Acids 54 (1996), 101-107.
17. C. Florio, F. Frausin, R. Vertua and R.M. Gaion, Involvement of P1 receptors in the effect of forskolin on cyclic AMP accumulation and export in PC12 cells, Biochem. Pharmacol. 57 (1999), 355-364.
18. C. Florio, F. Frausin, R. Vertua and R.M. Gaion, Amplification of the cyclic AMP response to forskolin in pheochromocytoma PC12 cells through adenosine A (2A) purinoceptors, J. Pharmacol. Exp. Ther. 290 (1999), 817-824.
19. F.G.R. Fowkes, Epidemiology of atherosclerotic arterial disease in the lower limbs, Eur. J. Vasc. Surg. 2 (1998), 283-291.
20. T.N. Gruber, Increased adenosine concentration in blood from ischaemic myocardium by AICA riboside: effects on flow, granulocyte and injury, Circulation 80 (1983), 1400-1411.
21. R.J. Haslam and G.M. Rosson, Effects of adenosine on adenosine cyclic 3′,5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation, Mol. Pharmacol. 11 (1975), 528-544.
22. + channels in cerebral ischemic preconditioning, Proc. Natl. Acad. Sci. USA 92 (1995), 4666-4670.
23. R.L. Kinlough Rathbone, M.A. Packham and J.F. Mustard, The effect of prostaglandin E1 on platelet function in vitro and in vivo, Br. J. Haematol. 19 (1970), 559-571.
24. J. Kloeze, Relationship between clinical structure and platelet aggregation activity, Biochem. Biophys. Acta 187 (1969), 285-292.
25. P.G. Kury, P.W. Ramwell and H.M. McConnel, The effect of prostaglandin E1 and E2 on the human erythrocyte as monitored by spin labels, Biochem. Biophys. Res. Commun. 56 (1974), 478-483.
26. F. Laghi Pasini, C. Frigerio, L. De Giorgi, L. Domini, S. Pecchi, P. Damiani, A. Acciavatti, P.L. Capecchi, N. Sodi, T. Provvedi, L. Volpi and T. Di Perri, Effect of adenosine i.v. infusion on peripheral haemodynamics, haemorheology and platelet behaviour in man, Clin. Hemorheol. 14 (1994), 709-722.
27. R. Lasila, M. Lepäntalo and O. Linfors, Peripheral arterial disease, natural outcome, Acta Med. Scand. 220 (1986), 295-298.
28. G.D.O. Lowe, Pathophysiology of critical limb ischaemia, in: Critical Limb Ischaemia: its Pathophysiology and Management, J. Dormandy and G. Stocks, eds, Springer-Verlag, Berlin, 1980, pp. 17-38.
29. N. Masaki, Y. Ohta, H.J. Shirataki, I. Ogata, S. Hayashi, S. Yamada, K. Hirata, S. Nagoshi and T. Tomiya, Hepatocyte membrane stabilization by prostaglandin E1 and E2: favourable effects on rat liver injury, Gastroenterol. 102 (1992), 572-576.
30. F.C. Mokken, M. Kedaria, C.P. Henny, M.R. Hardeman and A.W. Gelb, The clinical importance of erythrocyte deformability, a hemorheological parameter, Ann. Hematol. 64 (1992), 113-122.
31. C.E. Murry, R.B. Jennings and K.A. Reimer, Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium, Circulation 74 (1986), 1124-1136.
32. G.B. Nash, P.R.S. Thomas and J. Dormandy, Abnormal flow properties of white cells in patients with severe ischaemia of the leg, Br. Med. J. 296 (1988), 1699-1701.
33. F.J. Neumann, W. Waas, C. Diehm, T. Weiss, H.M. Haupt, R. Zimmermann, R. Tillmanns and W. Kübler, Activation and decreased deformability of neutrophils after intermittent claudication, Circulation 82 (1990), 922-929.
34. F. Ottani, M. Galvani, D. Ferrini, P. Sorbello, P. Limonetti, D. Pantoli and F. Rusticali, Prodromal angina limits infarct size. A role for ischaemic preconditioning, Circulation 91 (1995), 291-297.
35. J.D. Pearson, J.S. Carleton and J.L. Gordon, Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smooth-muscle cells in culture, Biochem. J. 190 (1980), 421-429.
36. C.J. Pitarys, R. Virmiani, H.D. Vildbill, Jr., E.K. Jackson and M.D. Forman, Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period, Circulation 83 (1991), 237-147.
37. V. Ralevic, K.A. Milner, K.A. Kirkpatrick and G. Burnstock, Flow-induced release of adenosine 5′-triphosphate from endothelial cells of the rat mesenteric arterial bed, Experientia 48 (1992), 31-34.
38. H.L. Reid, A.J. Barnes, P.J. Lock, P.J. Dormandy and T.L. Dormandy, A simple method for measuring erythrocyte deformability, J. Clin. Pathol. 29 (1976), 855-858.
39. G. Rudofsky, B. Altenhoff, P. Meyer and A. Lohmann, Intra-arterial perfusion with prostaglandin E1 in patients with intermittent claudication, Vasa 17(Suppl.) (1987), 47-51.
40. G. Rudofsky, Zur Wirkung von PGE1 am Ischaemiemodell, Klin. Wochenschrift 64 (1986), 257.
41. P. Scheffler, D. de la Hamette and G. Leipnitz, Therapeutic efficacy of intravenously applied prostaglandin E1, Vasa 28(Suppl.) (1989), 19-25.
42. P. Scheffler, P. de la Hamette, J. Gross, H. Müller and H. Schieffer, Intensive vascular training in stage lib of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin El or intravenous pentoxifylline during training, Circulation 90 (1994), 818-822.
43. K. Schrör and G. Hecker, Potent inhibition of superoxide anion generation by PgE1 and the PgE1 analog OP-106 in human PMNs, unrelated to its antiplatelet, PgI2-like activity, Vasa 17(Suppl.) (1987), 11-16.
44. K. Schrör, C. Thiemermann and P. Ney, Protection of the ischemic myocardium from reperfusion injury by prostaglandin E1 inhibition of ischemia induced neutrophil activation, Naunyn. Schmiedebergs. Arch. Pharmacol. 336 (1988), 268-274.
45. P.J. Simpson, J. Mickelson, J.C. Fantone, K.P. Gallagher and B.R. Lucchesi, Reduction of experimental canine myocardial infarct size with prostaglandin E1 inhibition of neutrophil migration and activation, J. Pharmacol. Exp. Ther. 244 (1988), 619-624.
46. J.D. Thornton, G.S. Liu, R.A. Olsson and G.M. Downey, Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction, Circulation 85 (1992), 659-665.
47. G. Trübenstein, S. von Bary, K. Breddin, C. Diehm, J.D. Gruss, H. Heinrich, S. Horsch, A. Kriessmann, U. Maas, M. Martin, N. Maurin and P. Scheffer, Intravenous prostaglandin E1 versus pentoxifylline in chronic arterial occlusive disease: a controlled randomized multicenter study, Vasa 28(Suppl.) (1989), 44-48.
48. Y. Ueda, K. Matsuo, T. Kamei, K. Kayashima and K. Konomi, Protective effect of prostaglandin E1 (PGE1) on energy metabolism and reticuloendothelial function in the ischemically damaged canine liver, Liver 9 (1989), 6-13.